397 related articles for article (PubMed ID: 12884349)
21. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines.
Dey S; Spring PM; Arnold S; Valentino J; Chendil D; Regine WF; Mohiuddin M; Ahmed MM
Clin Cancer Res; 2003 Apr; 9(4):1557-65. PubMed ID: 12684432
[TBL] [Abstract][Full Text] [Related]
22. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.
Reiss M; Brash DE; Muñoz-Antonia T; Simon JA; Ziegler A; Vellucci VF; Zhou ZL
Oncol Res; 1992; 4(8-9):349-57. PubMed ID: 1486218
[TBL] [Abstract][Full Text] [Related]
23. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma.
Hoffmann TK; Sonkoly E; Hauser U; van Lierop A; Whiteside TL; Klussmann JP; Hafner D; Schuler P; Friebe-Hoffmann U; Scheckenbach K; Erjala K; Grénman R; Schipper J; Bier H; Balz V
Oral Oncol; 2008 Dec; 44(12):1100-9. PubMed ID: 18487078
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA
Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362
[TBL] [Abstract][Full Text] [Related]
25. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
[TBL] [Abstract][Full Text] [Related]
27. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck.
Brennan JA; Boyle JO; Koch WM; Goodman SN; Hruban RH; Eby YJ; Couch MJ; Forastiere AA; Sidransky D
N Engl J Med; 1995 Mar; 332(11):712-7. PubMed ID: 7854378
[TBL] [Abstract][Full Text] [Related]
28. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma.
Sniezek JC; Matheny KE; Westfall MD; Pietenpol JA
Laryngoscope; 2004 Dec; 114(12):2063-72. PubMed ID: 15564824
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer.
Sauter ER; Ridge JA; Litwin S; Langer CJ
Clin Cancer Res; 1995 Nov; 1(11):1407-12. PubMed ID: 9815938
[TBL] [Abstract][Full Text] [Related]
30. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line.
Asada N; Tsuchiya H; Tomita K
Anticancer Res; 1999; 19(6B):5131-7. PubMed ID: 10697522
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
[TBL] [Abstract][Full Text] [Related]
32. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region.
Hauser U; Balz V; Carey TE; Grénman R; Van Lierop A; Scheckenbach K; Bier H
Head Neck; 2002 Sep; 24(9):868-73. PubMed ID: 12211051
[TBL] [Abstract][Full Text] [Related]
33. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.
Mandic R; Schamberger CJ; Müller JF; Geyer M; Zhu L; Carey TE; Grénman R; Dünne AA; Werner JA
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6845-52. PubMed ID: 16203773
[TBL] [Abstract][Full Text] [Related]
34. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
35. The bcl-2 gene status of human head and neck cancer cell lines.
Salo A; Servomaa K; Kiuru A; Pulkkinen J; Grénman R; Pekkola-Heino K; Rytömaa T
Acta Otolaryngol Suppl; 1997; 529():233-6. PubMed ID: 9288319
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic differences in cisplatin sensitivity of head and neck cancer cell lines: Correlation to lysosomal pH.
Nilsson C; Roberg K; Grafström RC; Ollinger K
Head Neck; 2010 Sep; 32(9):1185-94. PubMed ID: 20029982
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma.
Kothari V; Mulherkar R
Anticancer Res; 2012 Jan; 32(1):121-8. PubMed ID: 22213296
[TBL] [Abstract][Full Text] [Related]
38. Various forms of mutant p53 confer sensitivity to cisplatin and doxorubicin in bladder cancer cells.
Chang FL; Lai MD
J Urol; 2001 Jul; 166(1):304-10. PubMed ID: 11435891
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
Masunaga S; Uto Y; Nagasawa H; Hori H; Nagata K; Suzuki M; Kinashi Y; Ono K
Anticancer Res; 2006; 26(2A):1261-70. PubMed ID: 16619533
[TBL] [Abstract][Full Text] [Related]
40. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
